Hypotransferrinemia of chronically hemodialyzed patients

Artificial Organs

Volumn 23, Issue 12, 1999, Pages 1047-1054

  Kirschbaum, Barry ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ferritin; Hemodialysis; Iron; Oxygen free radical; Soluble transferrin receptor; Transferrin

Indexed keywords

FREE RADICALS; HEMODIALYZERS; IRON; NUTRITION; OXYGEN;

FERRITIN; HAEMODIALYSIS; HEMODIALYSIS PATIENT; INTRAVENOUS IRON; IRON AVAILABILITY; LABORATORY TEST; OXYGEN FREE RADICALS; SOLUBLE TRANSFERRIN RECEPTOR; TRANSFERRIN; TRANSFERRIN RECEPTORS;

DIALYSIS;

ALBUMIN; FERRITIN; IRON DEXTRAN; PREALBUMIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; IRON THERAPY; MALE; PRIORITY JOURNAL; PROTEIN DEFECT; TRANSFERRIN BLOOD LEVEL; TRANSFERRIN DEFICIENCY;

EID: 0033402736     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1999.06328.x     Document Type: Article

References (51)

1. 1. Daugirdas JT, Ing TS. Handbook of Dialysis, 2nd ed. Boston: Little, Brown, & Co., 1994.
2. 2. National Kidney Foundation. DOQI clinical practice guidelines for the treatment of the anemia of chronic renal failure. Amer J Kidney Dis 1997;30(Suppl 3):S192-212.
3. 3. Jandl JH. Physiology of red cells. The iron cycle. In: Jandl JH, ed. Blood. Textbook of Hematology, 2nd ed. Boston: Little, Brown & Co., 1996.
4. 4. Fielding J. Serum iron and iron binding capacity. Methods Hematology 1980;1:15-43.
5. 5. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. New Engl J Med 1974;290:1213-6.
6. 6. Aisen P. The transferrin receptor and the release of iron from transferrin. In: Hershko C, Konijn AM, Aisen P, eds. Progress in Iron Research. New York: Plenum, 1994:31-40.
7. 7. Baynes RD, Shih YJ, Cook JD. Mechanisms of production of the serum transferrin receptor. In: Hershko C, Konijn AM, Aisen P, eds. Progress in Iron Research. New York: Plenum, 1994:61-8.
8. 8. Richardson DR, Panka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acts 1997;1331:1-40.
9. 9. Kurer SB, Seifert B, Michel B, Ruegg R, Fehr J. Prediction of iron deficiency in chronic inflammatory rheumatic disease anaemia. Brit J Haematol 1995;91:820-6.
10. 10. Worwood M. The laboratory assessment of iron status - An update. Clin Chim Acta 1997;259:3-23.
11. 11. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-7.
12. 12. Morgan EH. Transferrin biochemistry, physiology, and clinical significance. Molec Aspects Med 1981;4:1-123.
13. 13. Braughler JM, Duncan LA, Chase RL. The involvement of iron in lipid peroxidation. Importance of ferric to ferrous ratios in initiation. J Biol Chem 1986;261:10282-9.
14. 14. Khoschsorur G, Bratschitsch G, Roob JM, Schaur R-J. Iron induced lipid peroxidation in whole blood in vitro as determined by malondialdehyde and luminol-enhanced chemiluminescence: implications for iron supplementation. Med Sci Res 1997;25:389-91.
15. 15. Galleano M, Puntarulo S. Role of antioxidants on the erythrocyte resistance to lipid peroxidation after acute iron overload in rats. Biochim Biophys Acta 1995;1271:321-6.
16. 16. Delmas_Beauvieux M-C, Combe C, Peuchant E, Carbonneau M-A, Dubourg L, de Precigout V, Aparicio M, Clerc M. Evaluation of red blood cell lipoperoxidation in hemodialyzed patients during erythropoietin therapy supplemented or not with iron. Nephron 1995;69:404-10.
17. 17. Gutteridge J, Quinlan GJ. Antioxidant protection against organic and inorganic oxygen radicals by normal human plasma: the important primary role for iron-binding and iron-oxidizing proteins. Biochim Biophys Acta 1993;1156:144-50.
18. 18. Loban A, Kime R, Powers H. Iron-binding antioxidant potential of plasma albumin. Clin Sci 1997;93:445-51.
19. 19. Lipinski P, Drapier J-C. Interplay between ferritin metabolism, reactive oxygen species, and nitric oxide. JBIC 1997;2: 559-66.
20. 20. Lin F, Girotti AW. Elevated ferritin production, iron containment, and oxidant resustance in hemin-treated leukemia cells. Arch Biochem Biophys 1997;346:131-41.
21. 21. Muntane J, Puig-Parellada P, Mitjavila MT. Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron dextran and deferoxamine. J Lab Clin Med 1995;126:435-43.
22. 22. Magnusson M, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron binding capacity as a risk factor for myocardial infarction. Circulation 1994;89: 102-8.
23. 23. Hubel CA, Kozlov AV, Kagan VE, Evans RW, Davidge ST, McLaughlin MK, Roberts JM. Decreased transferrin and increased transferrin saturation in sera of women with preeclampsia: implications for oxidative stress. Amer J Obstet Gynecol 1996;175:692-700.
24. 24. Reznick AZ, Cross CE, Hu M-L, Suzuki YJ, Khwaja S, Safadi A, Motchnik PA, Packer L, Halliwell B. Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochem J 1992;286:607-11.
25. 25. Steinbrecher VP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 1989;30:305-15.
26. 26. Mackness MI, Durrington PN. HDL: its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115:243-53.
27. 27. Fishbane S, Maesaka JK. Iron management in end stage renal disease. Amer J Kidney Dis 1997;29:319-33.
28. 28. Garibotto G, Russo R, Sofia A, Sala MR, Robaudo C, Moscatelli P, Deferrari G, Tizianello A. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. Kidney Int 1994;45:1432-9.
29. 29. Gretz N, Quintel M, Kranzlin B. Extracorporeal therapies in acute renal failure: Different therapeutic options. Kidney Int 1998;53(suppl 64):S57-S60.
30. 30. Rogaller M, Werner C, Bleyl J, Adam S, Jacobasch H-J, Albrecht DM. Blood compatible polymers in intensive care units: State of the art and current aspects of biomaterials research. Kidney Int 1998;53(suppl 64):S84-S90.
31. 31. Van Lenten BJ, Prieve J, Navab M, Hama S, Lusis AJ, Fogelman AM. Lipid induced changes in intracellular iron homeostasis in vitor and in vivo. J Clin Invest 1995;95:2104-10.
32. 32. Weiss G, Wachter H, Fuchs D. Linkage of cell mediated immunity to iron metabolism. Immunol Today 1995;16:495-500.
33. 33. Cairo G, Tacchini L, Pagliaghi G, Anzon E, Tomasi A, Bernelli-Zazzera A. Induction of ferritin syntheis by oxidative stress. J Biol Chem 1995;270:700-3.
34. 34. Bouton C, Hirling H, Drapier J-C. Redox modulation of iron regulatory proteins by peroxynitrite. J Biol Chem 1997;272: 19969-75.
35. 35. Halle M, Konig D, Berg A, Keul J, Baumstark MW. Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis 1997;128:235-40.
36. 36. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992;86:803-11.
37. 37. Reunanen A, Takkunen H, Knekt P, Seppanen R, Aromaa A. Body iron stores, dietary iron intake, and coronary heart disease. J Int Med 1995;238:223-30.
38. 38. Dabbagh AJ, Shwaery GT, Keaney JF, Frei B. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol 1997; 17:2638-45.
39. 39. Harris ED. Copper transport and metabolism: an update. J Trace Elements Exp Med 1998;11:163-76.
40. 40. Zanen AL, Adriaansen HJ, von Bommrl EF, Posthuma R, Th de Jong GM. Oversaturation of transferrin after intravenous ferrous gluconate in hemodialysis patients. Nephrol Dial Transplant 1996;11:820-4.
41. 41. Nappi AJ, Vass E. Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. Biochim Biophys Acta 1997;1336:295-301.
42. 42. Serdyuk AP, Morton RE. Resistance of lipoproteins from continuous ambulatory peritoneal dialysis patients to in vitron oxidation. Metabolism 1997;46:833-9.
43. 43. Nyyssonen K, Porkkala-Sarataho E, Kaikkonen J, Salonen JT. Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis 1997;130:223-33.
44. 44. Loughrey CM, Young IS, MeEnemy J. Oxidation of low density lipoprotein in patients on regular hemodialysis. Atherosclerosis 1994;110:185-93.
45. 45. Thomas SR, Neuzil J, Stocker R. Cosupplementation with coenzyme Q prevents the prooxidant effect of alphatocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler Thromb Vasc Biol 1996;16:687-96.
46. 46. Durken M, Nielsen P, Knobel S, Finckh B, Herrnring C, Dresow B, Kohlschutter B, Stockschlader M, Kruger WH, Kohlschutter A, Zander AR. Non-transferrin-bound iron in serum of patients receiving bone marrow transplants. Free Rad Biol Med 1997;22:1159-63.
47. 47. Masawe A, Rwabwago-Atenyi J. Serum protein and transferrin determinations to distinguish kwashiorkor from iron deficiency anaemia. Arch Dis Child 1973;48:927-30.
48. 48. Lowrie E, Lew N. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Amer J Kidney Dis 1990;15:458-82.
49. 49. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Amer Soc Nephrol 1996;7:2654-7.
50. 50. Drueke TB, Barany P, Cazzola M, Eschbach JW, Grutzmacher P, Kaltwasser JP, MacDougall IC, Pippard M, Shaldon S, van Wyck D. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997;48:1-8.
51. 51. Fishbane S, Galgano C, Langley RC, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997;52:217-222.